Symptoms and General Pathology

All Conditions

Neoplasms

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Diseases and Abnormalities at or Before Birth

Nervous System Diseases

Skin and Connective Tissue Diseases

Rare Diseases

Recurrence

Wilms Tumor

Nerve Sheath Neoplasms

Neurofibrosarcoma

Rhabdoid Tumor

Neoplasms by Histologic Type

Kidney Neoplasms

Urologic Neoplasms

Urogenital Neoplasms

Syndrome

Neoplastic Syndromes, Hereditary

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Kidney Diseases

Urologic Diseases

Male Urogenital Diseases

Genetic Diseases, Inborn

Neoplasms, Nerve Tissue

Nervous System Neoplasms

Peripheral Nervous System Neoplasms

Peripheral Nervous System Diseases

Neuromuscular Diseases

Fibrosarcoma

Neoplasms, Fibrous Tissue

Neoplasms, Connective Tissue

Neoplasms, Connective and Soft Tissue

Sarcoma

Neurofibromatoses

Neurofibroma

Wilms' Tumor

Malignant Peripheral Nerve Sheath Tumor

Soft Tissue Sarcoma

Neurofibromatosis

Participants will have any type of Wilms tumor or nephroblastoma

Participants will have any Rhabdoid tumor

Participants will have progressive, relapsed, unresectable or metastatic MPNST

Participants must not qualify for Cohorts A, B, or C but have a solid tumor (no hematologic malignancies including lymphoma) for which there is specific evidence that this particular patient's tumor may benefit from selinexor.

This phase II study will initially treat all patients, including adult patients, at the pediatric Selinexor RP2D of 35 mg/m2 (no maximum dose) once weekly using a liquid suspension .

Selinexor

Michael Ortiz, MD

Julia Glade Bender, MD

Rachana Shah, MD

Thomas Cash, MD

Elizabeth Mullen, MD

James Geller, MD

The purpose of this study is to find out whether selinexor is an effective treatment for people under the age of 51 who have a relapsed/refractory Wilms tumor, rhabdoid tumor, MPNST, or another solid tumor that makes a higher than normal amount of XPO1 or has genetic changes that increase the activity of XP01.

A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors

A Multi-Center Phase II Study of Selinexor in Treating Recurrent or Refractory Wilms Tumor and Other Pediatric Solid Tumors

• Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.

To define the antitumor activity of Selinexor in relapsed and refractory Wilms tumor by measuring the Overall Response Rate, defined as Complete Response + Partical Response

Memorial Sloan Kettering Cancer Center

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors	NCT05985161	Wilms Tumor Rhabdoid Tumor Malignant Perip... MPNST Nephroblastoma XPO1 Gene Mutat... Solid Tumor	Selinexor	12 Months -	Memorial Sloan Kettering Cancer Center
A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors	NCT05985161	Wilms Tumor Rhabdoid Tumor Malignant Perip... MPNST Nephroblastoma XPO1 Gene Mutat... Solid Tumor	Selinexor	12 Months -	Memorial Sloan Kettering Cancer Center

Spots Global Cancer Trial Database for xpo1 gene mutation